Ophthalmic Equipment News
-
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome
BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM ...
-
Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery. Up to 80% ...
-
Nukute pitched as one of the “TOP12 Health Techpreneurs? at MEDICA2021
Nukute pitched at the “TOP12 Health Techpreneurs″ at MEDICA2021 From over 300 applicants all over the world, Nukute pitched as one of the “TOP12 Health Techpreneurs″ at the 13th Healthcare Innovation World Cup, held at the 9th MEDICA CONNECTED HEALTHCARE FORUM on Monday, 15 November 2021. Nukute didn’t get to bring home victory – the first prize went to ...
By Nukute Oy
-
Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. The breakthrough findings position the ...
-
Ivantis Announces Settlement of Glaukos Patent Litigation
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. Under the agreement’s terms, Ivantis has agreed to pay a total of ...
-
Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. This significant milestone represents the longest continuous follow-up of a MIGS device pivotal trial and comes on the ...
-
Ivantis Recognized For Innovation, Excellence And Company Culture
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma patients, as well as its ...
-
Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation” — the highest designation of any MIGS device ...
-
First-Ever Four-Year MIGS Pivotal Trial Results Show Hydrus Microstent Significantly Reduces Need for Invasive Surgery and Subsequent Glaucoma Medication
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever, four-year follow-up data for a MIGS device in an FDA pivotal trial. The latest findings from the HORIZON study confirm the benefits of the Hydrus Microstent seen in earlier follow-up and ...
-
Mojo Vision Working with FDA, Nonprofit Organization to Assist People with Low Vision
SARATOGA, Calif.--(BUSINESS WIRE) https://www.businesswire.com/news/home/20200116005187/en/Mojo-Vision-Working-FDA-Nonprofit-Organization-Assist --Mojo Vision, the Invisible Computing company, today announced a pair of initiatives integral to its goal of assisting people with low or impaired vision. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Mojo ...
-
Ivantis Announces 3 Year Results of Australian SPECTRUM Registry for Hydrus Microstent
Ivantis today announced long term results of the Australian cohort of the Global SPECTRUM registry. SPECTRUM is a post market patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with open-angle glaucoma in conjunction with cataract surgery or as a stand-alone procedure outside the United States. The SPECTRUM Registry was conceived in ...
-
Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent
SPECTRUM, the world’s largest single-device registry in ophthalmology, has completed enrollment. The announcement was made today by Ivantis Inc., a company dedicated to developing new and innovative solutions for glaucoma. SPECTRUM is a patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate primary open-angle ...
-
LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drug
Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National Institutes of Health awarded LayerBio a $1.2 million small business grant to develop its sustained-release formulation of the glaucoma drug travoprost. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you